| pubmed-article:11185927 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11185927 | lifeskim:mentions | umls-concept:C0036341 | lld:lifeskim |
| pubmed-article:11185927 | lifeskim:mentions | umls-concept:C0024487 | lld:lifeskim |
| pubmed-article:11185927 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11185927 | pubmed:dateCreated | 2001-1-19 | lld:pubmed |
| pubmed-article:11185927 | pubmed:abstractText | Magnetic resonance spectroscopy (MRS) has been increasingly used to investigate the in vivo biochemistry of particular regions of the brain in patients with schizophrenia. We review the literature and discuss the theoretical constructs that form the presumed impetus for these studies in light of the current methodological limitations. Future directions are noted. | lld:pubmed |
| pubmed-article:11185927 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11185927 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11185927 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11185927 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11185927 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11185927 | pubmed:issn | 0004-8674 | lld:pubmed |
| pubmed-article:11185927 | pubmed:author | pubmed-author:WoodS JSJ | lld:pubmed |
| pubmed-article:11185927 | pubmed:author | pubmed-author:PantelisCC | lld:pubmed |
| pubmed-article:11185927 | pubmed:author | pubmed-author:DesmondPP | lld:pubmed |
| pubmed-article:11185927 | pubmed:author | pubmed-author:MaruffPP | lld:pubmed |
| pubmed-article:11185927 | pubmed:author | pubmed-author:VelakoulisDD | lld:pubmed |
| pubmed-article:11185927 | pubmed:author | pubmed-author:VanceA LAL | lld:pubmed |
| pubmed-article:11185927 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11185927 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:11185927 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11185927 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11185927 | pubmed:pagination | 14-25 | lld:pubmed |
| pubmed-article:11185927 | pubmed:dateRevised | 2009-11-11 | lld:pubmed |
| pubmed-article:11185927 | pubmed:meshHeading | pubmed-meshheading:11185927... | lld:pubmed |
| pubmed-article:11185927 | pubmed:meshHeading | pubmed-meshheading:11185927... | lld:pubmed |
| pubmed-article:11185927 | pubmed:meshHeading | pubmed-meshheading:11185927... | lld:pubmed |
| pubmed-article:11185927 | pubmed:meshHeading | pubmed-meshheading:11185927... | lld:pubmed |
| pubmed-article:11185927 | pubmed:meshHeading | pubmed-meshheading:11185927... | lld:pubmed |
| pubmed-article:11185927 | pubmed:meshHeading | pubmed-meshheading:11185927... | lld:pubmed |
| pubmed-article:11185927 | pubmed:meshHeading | pubmed-meshheading:11185927... | lld:pubmed |
| pubmed-article:11185927 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11185927 | pubmed:articleTitle | Magnetic resonance spectroscopy and schizophrenia: what have we learnt? | lld:pubmed |
| pubmed-article:11185927 | pubmed:affiliation | Cognitive Neuropsychiatry Unit, Mental Health Research Institute of Victoria, Parkville, Australia. alasdair.vance@med.monash.edu.au | lld:pubmed |
| pubmed-article:11185927 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11185927 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:11185927 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11185927 | lld:pubmed |
